Image
AUDIO
Image

Posted by Ryan S

Brand-new treatment for blood cancer unveiled

DLBCL is an aggressive blood cancer, with nearly 5,500 new diagnoses in the UK each year. For around 700 of these patients whose cancer has returned or has not responded to at least two prior treatments, prognosis is poor.

There are few treatments available for this patient population, and these are typically administered intravenously, via a needle or tube inserted into a vein, in a hospital setting. While epcoritamab is also given in a hospital setting, it is administered subcutaneously, meaning it is an injection under the skin.

AbbVie has today announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly® (epcoritamab) as a treatment option for adults with diffuse DLBCL whose cancer has returned or has not responded to at least two previous treatments, only if they have previously had polatuzumab vedotin or it is contraindicated or not tolerated.

Ryan spoke to Chris Fox, professor of haematology at the University of Nottingham and Jane Thacker.

Ads help us keep this site online